12/24/2009

Synta Pharmaceuticals started a midstage study to test the efficacy of its synthetic, small-molecule drug STA-9090 in as many as 55 patients with advanced gastrointestinal stromal tumors. The treatment also is being tested in a Phase II trial for nonsmall-cell lung cancer.

Related Summaries